• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation†‡

  1. Min Fang MD, PhD1,2,3,§,*,
  2. Barry Storer PhD1,
  3. Brent Wood MD2,4,
  4. Boglarka Gyurkocza MD1,5,
  5. Brenda M. Sandmaier MD1,5,
  6. Frederick R. Appelbaum MD1,2,5

Article first published online: 16 SEP 2011

DOI: 10.1002/cncr.26539

Issue

Cancer

Cancer

Volume 118, Issue 9, pages 2411–2419, 1 May 2012

Additional Information

How to Cite

Fang, M., Storer, B., Wood, B., Gyurkocza, B., Sandmaier, B. M. and Appelbaum, F. R. (2012), Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer, 118: 2411–2419. doi: 10.1002/cncr.26539

Author Information

  1. 1

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

  2. 2

    Seattle Cancer Care Alliance, Seattle, Washington

  3. 3

    Department of Pathology, University of Washington, Seattle, Washington

  4. 4

    Department of Laboratory Medicine, University of Washington, Seattle, Washington

  5. 5

    Division of Medical Oncology, University of Washington, Seattle, Washington

  1. §

    Fax: (206) 288-7567

*Fred Hutchinson Cancer Research Center, 825 Eastlake Avenue East, G7-500, Seattle, WA 98109-1023

  1. †

    We thank Gary Schoch, a clinical research database manager from Fred Hutchinson Cancer Research Center, and Stacie Thomas (secretary) and Lisa Zhang (clinical technologist) from the Cytogenetics Laboratory of Seattle Cancer Care Alliance for their help with data collection.

  2. ‡

    M.F. and F.R.A. conceptualized the project. M.F. and B.W. collected and reviewed all the data. B.G. and B.M.S. collected nonmyeloablative data. M.F. and B.S. analyzed the data. All authors contributed to writing and editing the article.

  3. §

    Fax: (206) 288-7567

Publication History

  1. Issue published online: 20 APR 2012
  2. Article first published online: 16 SEP 2011
  3. Manuscript Accepted: 10 AUG 2011
  4. Manuscript Revised: 27 JUL 2011
  5. Manuscript Received: 1 JUN 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1177K)

REFERENCES

  • 1
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 4075-4083.
  • 2
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
  • 3
    Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474.
  • 4
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 5
    Marcucci G, Mrozek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol. 2004; 22: 2410-2418.
  • 6
    Freireich EJ, Cork A, Stass SA, et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia. 1992; 6: 500-506.
  • 7
    Frohling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002; 20: 2480-2485.
  • 8
    Wood BL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007; 27: 551-575.
  • 9
    Wood B. Nine-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006; 130: 680-690.
  • 10
    San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001; 98: 1746-1751.
  • 11
    Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004; 89: 528-540.
  • 12
    Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008; 26: 4944-4951.
  • 13
    Appelbaum FR. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol. 1999; 36: 401-410.
  • 14
    Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996; 87: 4789-4796.
  • 15
    Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995; 85: 2632-2638.
  • 16
    Shaffer LG, Slovak ML, Campbell LJ, eds. An International System for Human Cytogenetic Nomenclature. Unionville, CT: S. Karger Publishers, Inc.; 2009.
  • 17
    Shaffer LG, Tommerup N. An International System for Human Cytogenetic Nomenclature. Unionville, CT: S. Karger Publishers, Inc, 2005.
  • 18
    Wood BL. Ten-color immunophenotyping of hematopoietic cells [serial online]. Curr Protoc Cytom. 2005;Chapter 6:Unit 6.21.
  • 19
    Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011; 29: 1190-1197.
  • 20
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75: 555-562.
  • 21
    Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer. 2006; 106: 839-847.
    Direct Link:
View Full Article (HTML) Get PDF (1177K)